

UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF CALIFORNIA


OFFICE OF THE CLERK
333 WEST BROADWAY, SUITE 420
SAN DIEGO, CALIFORNIA 92101

OFFICIAL BUSINESS

FILED
NOV 27 2013
CLERK U.S. DISTRICT COURT
SOUTHERN DISTRICT OF CALIFORNIA
BY DEPUTY

ELECTRONIC
SERVICE
REQUESTED

POSTAGE
NECESSARY
FOR MAILING



NOV 27 2013
\$ 00.384
MAIL PERMIT NO. 1000
SAN DIEGO, CA 92101

AJD

Joel B. Weinrich
2651 Mercury Drive
Unit B
Lemon Grove, CA 91945

NIXIE 918 DE 1 0011/20/13

RETURN TO SENDER
ATTEMPTED - NOT KNOWN
UNABLE TO FORWARD

BC: 92101380620 *0818-05004-13-13

~~92101380620~~



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

**UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF CALIFORNIA**

**IN RE INCRETIN-BASED
THERAPIES PRODUCTS LIABILITY
LITIGATION**

Case No. 13-md-2452-AJB-MDD
As to all related and member cases

**ORDER GOVERNING THE
PRODUCTION OF
ELECTRONICALLY STORED
INFORMATION**

This order relates to the production of documents and supplements all other discovery rules and orders as between defendants Merck Sharp & Dohme (“Merck”) and Novo Nordisk Inc. (“Novo”), collectively “Defendants,” and all plaintiffs in this litigation. It streamlines Electronically Stored Information (“ESI”) production to promote a “just, speedy, and inexpensive determination” of this action, as required by the Federal Rules of Civil Procedure.

A. Already-Produced Documents

On April 24, 2013, Merck produced the New Drug Application (“NDA”) and Investigational New Drug (“IND”) Application files for Januvia and Janumet, as collected on December 11, 2012. On April 24, 2013, Merck also produced the FDA-approved package inserts for Januvia and Janumet. Together, this production included